Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder

Psychiatric Services

Volumn 49, Issue 8, 1998, Pages 1029-1033

  Reid, William H ^a,d   Mason, Mark ^b   Hogan, Thomas ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Texas Dept Mental Hlth Mental R

^c NOVARTIS PHARMA AG   (Switzerland)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE;

ADULT; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PROPHYLAXIS; REGISTER; SCHIZOIDISM; SCHIZOPHRENIA; SUICIDE;

EID: 0031904437     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/ps.49.8.1029     Document Type: Article

References (15)

1. Berren MR, Hill KR, Merikle E, et al: Serious mental illness and mortality rates. Hospital and Community Psychiatry 45:604-605, 1994
2. Black DW: Mortality in schizophrenia: the Iowa record-linkage study: a comparison with general population mortality. Psychosomatics 29:55-60, 1988
3. Allebeck P: Schizophrenia: a life-shortening disease. Schizophrenia Bulletin 15:81-89, 1989
4. Newman SC, Bland RC: Mortality in a cohort of patients with schizophrenia: a record linkage study. Canadian Journal of Psychiatry 36:239-245, 1991
5. Westermeyer JF, Harrow M, Marengo JT: Risk for suicide in schizophrenia and other psychotic and nonpsychotic disorders. Journal of Nervous and Mental Disease 179: 259-266, 1991
6. Caldwell CB, Gottesman II: Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophrenia Bulletin 16:571-589, 1990
7. Chiles JA, Davidson P, McBride D: Effects of clozapine on the use of seclusion and restraint at a state hospital. Hospital and Community Psychiatry 45:269-271, 1994
8. Lieberman JA, Safferman AZ, Pollack S, et al: Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. American Journal of Psychiatry 151:1744-1752, 1994
9. Meltzer HY, Okayli G: Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. American Journal of Psychiatry 152:183-190, 1995
10. Reid WH, Mason M, Toprac M: Savings in hospital bed-days related to treatment with clozapine. Hospital and Community Psychiatry 45:261-264, 1994
11. Reid WH, Mason M: Psychiatric hospital utilization in patients treated with clozapine for up to 4.5 years in a state mental healthcare system. Journal of Clinical Psychiatry 59:189-194, 1998
12. Wilson WH, Claussen AM: 18-month outcome of clozapine treatment for 100 patients in a state psychiatric hospital. Psychiatric Services 46:386-389, 1995
13. Walker AM, Lanza LL, Arellano A, et al: Mortality in current and former users of clozapine. Epidemiology 8:671-677, 1997
14. 1994 World Health Statistics Annual. Geneva, Switzerland, World Health Organization, 1995
15. Mortensen PB, Juel K: Mortality and causes of death in first-admitted schizophrenic patients. British Journal of Psychiatry 163:183-189, 1991